Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ASMB
SELLAssembly Biosciences, Inc. · Healthcare · United States · $506M · Avg Vol: $6M/d
COMPANY DESCRIPTION
Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on developing new oral therapeutics for serious viral diseases, with a primary focus on chronic Hepatitis B virus (HBV) infection. The company leverages its proprietary core inhibitor pipeline to address a significant global health challenge. It operates as a specialized biotech firm dedicated to innovative antiviral drug discovery.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.3M | 0 | 7.2M | 28.5M | 72.3M | 84.4% | 71.1M | 45.5M | 32.3M | -33.2% |
| EPS | -36.00 | -4.74 | -3.70 | -2.52 | -0.55 | — | 0.08 | 0.14 | -2.10 | — |
| Shares | 4.0M | 19.8M | 19.8M | 19.8M | 15.9M | +295.4% | 19.8M | — | — | — |
| Debt | 6.5M | 3.5M | 2.3M | 3.1M | 2.6M | -20.2% | 2.5M | — | — | — |
| Equity | 168.9M | 82.7M | 41.1M | 33.4M | 206.8M | 5.2% | — | — | — | — |
| Op CF | -93.4M | -84.5M | 22.7M | -51.1M | -41.1M | — | -39.8M | — | — | — |
| Inv CF | 26.5M | 90.6M | -69.1M | 40.2M | -113.5M | — | — | — | — | — |
| Fin CF | 53.1M | 0.6M | 13.8M | 29.4M | 174.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ASMB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ASMB | Assembly Biosciences, Inc.(you) | $506M | 23 | SELL |
| RZLT | Rezolute, Inc. | $480M | 23 | SELL |
| ZURA | Zura Bio Limited | $496M | 22 | SELL |
| ARTV | Artiva Biotherapeutics, Inc. | $487M | 26 | SELL |
| ARVN | Arvinas, Inc. | $518M | 20 | STRONG SELL |
| LRMR | Larimar Therapeutics, Inc. | $416M | 23 | SELL |
| NVCT | Nuvectis Pharma, Inc. | $609M | 25 | SELL |
| BNTC | Benitec Biopharma Inc. | $394M | 24 | SELL |
| FDMT | 4D Molecular Therapeutics, Inc. | $526M | 28 | SELL |
| CBIO | Crescent Biopharma, Inc. | $602M | 26 | SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.6%